Dr. Roy Peters, Chief Medical OfficerPeters Medical Research (PMR) serves as that essential bridge, connecting scientific innovation with patients, clinical needs and real-world experience. Building on nearly two decades of clinical research, PMR is working to make High Point, North Carolina, a destination for innovative trials and emerging treatments.
“Our goal is to ensure that patients do not have to live near a major academic medical center to participate in meaningful research or access promising new treatment options,” says Dr. Roy Peters, chief medical officer. “We want to bring the future of medicine to High Point while giving our community an active role in shaping that future.”
PMR combines a 21,000-square-foot research facility with access to a database of more than 250,000 potential participants across a wide range of conditions, backgrounds and clinical needs. Located in the Piedmont Triad, PMR can also draw from a population of more than 1.6 million people across High Point, Greensboro, Winston-Salem and surrounding communities, expanding the pool available for clinical research. These resources allows the organization to identify qualified candidates efficiently while giving sponsors access to patient populations that may be underrepresented in traditional research settings.
For sponsors, the difference becomes tangible when an ambitious protocol reaches the real world. PMR has identified hundreds of potential candidates for complex studies, enrolled approximately two dozen participants in a migraine trial in about one month and completed randomization for an obesity study in fewer than six weeks. Behind each milestone is a capability that can change the trajectory of a trial: turning a difficult recruitment target into an achievable plan and helping a promising therapy advance without unnecessary delay. Such performance can be particularly valuable for studies with demanding enrollment criteria, narrow recruitment windows or specialized participant requirements.
-
We want to bring the future of medicine to High Point while giving our community an active role in shaping that future.
This combination of reach, agility and execution allows PMR to do more than enroll participants quickly. It gives sponsors confidence that an opportunity can move from the drawing board to an active, productive study and gives patients earlier opportunities to participate in the development of potentially important new treatments.
PMR is now expanding its relationships with pharmaceutical companies, contract research organizations, biotechnology innovators, and leading investigators. The objective is not simply to conduct more trials, but to attract the right trials, studies that address important unmet needs and offer meaningful possibilities for patients throughout the Piedmont Triad and beyond.
Each partnership creates an opportunity to bring accomplished scientists, clinicians, research professionals and emerging innovators to High Point. In turn, the region becomes an active contributor to medical advances with national and global significance. High-quality research can strengthen local healthcare, broaden access to innovation and demonstrate that scientific excellence is not limited to traditional research hubs.
PMR’s next chapter is therefore about more than organizational growth. It is about expanding what community-based clinical research can accomplish. By creating a place where global innovation meets local medicine, Peters Medical Research is helping ensure that High Point does not simply benefit from the future of healthcare—it helps shape it.
Selecting Clinical Trial Services For Reliable Study Execution
Clinical trial procurement often turns on a gap between protocol ambition and what a research site can actually deliver. A sponsor may have a sound study design yet lose time when enrollment assumptions prove optimistic or qualified participants are difficult to identify. Site limitations can then compound the problem once recruitment begins. Every week lost at the site level can ripple into broader sponsor timelines. For buyers, the central question is not whether a provider can open a study. It is whether the provider can translate protocol requirements into dependable participant flow without adding avoidable delay.
Recruitment deserves close scrutiny because the headline database size can be misleading. A large contact pool has limited value if records are poorly matched to inclusion criteria or outreach cannot produce responsive candidates. Buyers need evidence that a provider understands the populations available to it and can screen against study requirements early. Recruitment also has to remain productive when eligibility rules narrow the field. Geographic reach matters when it extends access beyond patients who typically enter research through major academic centers, especially for protocols that depend on broader representation.
Execution capacity becomes a different pressure point once candidates begin entering the study. Complex protocols can demand repeated visits and specialized procedures, while investigators and research staff still have to keep scheduling disciplined. A provider needs enough physical capacity to handle study activity without creating bottlenecks, and its clinical personnel must be able to manage protocol requirements consistently. Narrow enrollment windows leave little tolerance for handoffs that slow appointments or leave sponsor teams waiting for answers. Buyers should probe how staffing depth and facility capacity hold up when several study demands converge.
Protocol fit should also be examined against the intended trial phase and patient population. Phase 2 through phase 4 studies place different demands on participant flow and visit management. A provider that already works across those phases can reduce the amount of adjustment required when a new protocol arrives. Diversity within the available participant base can be equally important when a study needs access to populations that are difficult to reach through traditional research centers. The useful question is whether the site’s real patient access matches the protocol on paper. Screening history can reveal whether apparent patient volume holds up once protocol exclusions are applied.
“Peters Medical Research’s reach across the Piedmont Triad gives sponsors access to a broad patient pool outside a major academic center.”
Speed, then, should be treated as an output rather than a promise. Fast enrollment is useful only when candidate identification remains disciplined, and study conduct keeps pace with recruitment. A credible clinical trial services partner should give buyers confidence in the front end of participant identification and in the work required after enrollment. Sponsor timelines become less dependent on feasibility assumptions that cannot be supported at the site level.
Peters Medical Research warrants close consideration where recruitment depth and site capacity dominate the buying decision. It supports phase 2 through phase 4 studies from a 21,000-square-foot research facility in High Point, North Carolina and draws on a database of more than 250,000 potential participants. Its reach across the Piedmont Triad gives sponsors access to a broad patient pool outside a major academic center. Peters Medical Research combines that recruitment base with physicianled study oversight and dedicated clinical research staff supporting study coordination. Enrollment-sensitive protocols leave little room for site-level delay and depend on real patient access.
...Read more
